ClinicalTrials.gg
CompletedNCT07739368Updated Jul 31, 2026

Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel Disease

A Phase 3 interventional study of Ferric Maltol and Placebo Oral Capsule in Iron Deficiency Anaemia, sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. (part of Beijing Aosaikang Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Sep 2021, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.

Enrollment
5th of 12
122 · median 78
Started
2021
with 1 other
Phase 3
7 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 3, and was the 12th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →

About ferric maltol

ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing ferric maltol in Anemia, Iron-Deficiency as a file.
02

Study summary

The purpose of this study is to determine whether Ferric Maltol, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

03

Conditions studied

  • Iron Deficiency Anaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of signing the form, male or female;
  • UC or CD, with a Simple Clinical Colitis Activity Index (SCCAI) score \< 5 or a Crohn's Disease Activity Index (CDAI) score \< 220 at the screening visit;
  • Anaemia, with levels tested at the screening visit as follows: Hb ≥ 85 g/L and \< 110 g/L for females, Hb ≥ 85 g/L and \< 120 g/L for males;
  • SIron deficiency, defined as ferritin \< 30 µg/L at the screening visit, or ferritin \< 100 µg/L and transferrin sa

Exclusion criteria

Exclusion Criteria:

  • Anaemia due to any cause other than iron deficiency, including but not limited to: untreated or untreatable severe malabsorption syndrome;
  • Subjects who have received the following treatments within 12 weeks prior to randomization

    1. Blood transfusion
    2. Erythropoietin
    3. Prolyl hydroxylase inhibitors
  • Subjects who have received the following treatments within 4 weeks prior to screening

    1. Oral/intramuscular/intravenous iron preparations (including sustained-release iron preparations)
    2. known to induce anaemia, including but not limited to methotrexate, cyclosporine A, or tacrolimus
    3. Traditional Chinese medicine prescriptions, herbs, or proprietary Chinese medicines with blood-tonifying effects (with anaemia as an indication in the package insert)
  • Vitamin B12 or folic acid measured at the screening visit was below the lower limit of normal;
  • Subjects with known or allergy to ferric maltol or any component of the medicinal product;
  • Subjects with known to iron preparation therapy, such as hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or lead poisoning-induced anaemia;
  • Subjects with creatinine > 1.5 times the measured at the screening visit;
  • Subjects with (ALT) or aspartate aminotransferase (AST) levels ≥ 5 times the upper limit of normal measured at the screening visit;
  • Subjects with severe cardiovascular, hepatic, renal, hematological, gastrointestinal, immune, endocrine, metabolic, or central nervous system diseases, which in the investigator's opinion might adversely affect the subject's safety and/or the efficacy of the investigational drug;
  • Subjects with a history of within the past 5 years, except for excised basal cell carcinoma in situ;
  • Subjects with significant neurological or psychiatric disorders leading to disorientation, memory impairment, or inability to report accurately, which might interfere with treatment compliance, study conduct, or interpretation of results (e.g., Alzheimer's disease, depression, anxiety, schizophrenia or other psychiatric disorders, alcohol or drug abuse);
  • Subjects who have participated in another interventional clinical study within 4 weeks prior to randomization or would participate during this study;
  • Subjects who are inmates of psychiatric hospitals or prisons;
  • Female subjects who are pregnant or breastfeeding;
  • Other situations deemed by the investigator as unsuitable for the patient to participate in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Active comparator
    Ferric Maltol

    30mg capsules, taken orally twice a day

    Drug: Ferric Maltol

  • Placebo comparator
    Matching placebo capsules for Ferric Maltol

    taken orally twice a day

    Drug: Placebo Oral Capsule

Interventions

  • 30 mg capsules to be taken orally twice a day for 12 weeks

  • DrugPlacebo Oral Capsule

    Matching placebo capsules for Ferric Maltol to be taken orally twice a day for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in Haemoglobin (Hb) Concentration From Baseline to Week 12

    Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit. A mixed-effects model for repeated measures (MMRM) was used for the statistical analysis of the change in Hb from baseline after treatment. The model used the change in Hb from baseline at each post-treatment time point as the dependent variable, baseline Hb as a covariate, treatment group, visit, disease at screening (UC or CD), treatment group × visit interaction, and baseline Hb × visit interaction as fixed effects, and subject as a random effect.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Proportion of Subjects That Achieved ≥10 g/L Change From Baseline in Hb Concentration at Week 12

    Proportion of subjects with an increase in Hb concentration of ≥10 g/L at Week 12 compared to baseline.

    Time frame: Baseline to Week 12

  2. Proportion of Subjects That Achieved ≥20 g/L Change From Baseline in Hb Concentration at Week 12

    Proportion of subjects with an increase in Hb concentration of ≥20 g/L at Week 12 compared to baseline.

    Time frame: Baseline to Week 12

  3. Proportion of subjects with Hb concentration within the normal range at Week 12

    Proportion of subjects with Hb concentration within the normal range at Week 12 compared to baseline.

    Time frame: Baseline to Week 12

  4. Change in Hb concentration from baseline to Week 4

    Defined as the change in Hb concentration from Baseline to Week 4. A mixed-effects model for repeated measures, as used for the primary efficacy endpoint, was employed.

    Time frame: Baseline to Week 4

  5. Change in Hb concentration from baseline to Week 8

    Defined as the change in Hb concentration from Baseline to Week 8. A mixed-effects model for repeated measures, as used for the primary efficacy endpoint, was employed.

    Time frame: Baseline to Week 8

  6. Change in Serum Iron Concentration From Baseline to Week 12

    Time frame: Baseline to Week 12

  7. Change in Serum Ferritin Concentration From Baseline to Week 12

    Time frame: Baseline to Week 12

  8. Changes in Transferrin From Baseline to Week 12

    Time frame: Baseline to Week 12

  9. Changes in Total Iron-binding Capacity From Baseline to Week 12

    Time frame: Baseline to Week 12

  10. Change in Transferrin Saturation From Baseline to Week 12

    Time frame: Baseline to Week 12

  11. Change in Soluble Transferrin Receptor from Baseline to Week 12

    Time frame: Baseline to Week 12

07

Study locations

1 site
  • Jiangsu Aosaikang Pharm
    Nanjing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2025, 41 months.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 31, 2026
StartActual
Sep 1, 2021
Primary completionActual
Feb 20, 2025
CompletionActual
Mar 20, 2025
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07739368
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Sep 1, 2021
Primary completion
Feb 20, 2025
Completion
Mar 20, 2025
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion